Form 4: DexCom Director Steven Altman Reports Stock Award

Director Steven Altman reported the acquisition of 2,613 shares of DexCom common stock through a restricted stock unit (RSU) award.

Summary

• On May 22, 2024, Steven Altman, a director of DexCom Inc., acquired 2,613 shares of common stock through a restricted stock unit (RSU) award.
• The RSU award vests on the earlier of the one-year anniversary of the grant date or the date of DexCom's 2025 Annual Meeting of Stockholders.
• Altman directly owns 2,613 shares and indirectly owns 56,017 shares through a trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard disclosure of stock ownership. The acquisition of shares by a director is generally viewed positively, but this is a routine filing.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Future Outlook

The RSU award will vest on the earlier of the one-year anniversary of the grant date or the date of DexCom's 2025 Annual Meeting of Stockholders, indicating a future event tied to stock ownership.

Industry Context

This filing is a routine disclosure of stock ownership changes by a company insider, which is common in the healthcare and medical device industry.

Stakeholder Impact

• The acquisition of shares by a director may have a slightly positive impact on shareholder sentiment.

Key Dates